

# Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS

## MSACL 2016 EU

Nicola Gray<sup>1</sup>, Stuart Snowden<sup>2</sup>, Min Kim<sup>2</sup>, Chris Titman<sup>1</sup>,  
Cristina Legido-Quigley<sup>2</sup>

<sup>1</sup>Shimadzu UK, Milton Keynes, UK

<sup>2</sup>King's College London, UK

## Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS

### Introduction

High-throughput and unbiased global profiling metabolomic approaches provide a suitable platform to analyse variations in metabolite levels, offering insights into mechanisms of disease through the discovery of novel biomarkers. Targeted approaches, however, offer a more specific, sensitive and quantitative measure for selected compounds. Here we investigate biochemical changes in enzymatic and metabolic processes at the cellular level in patients with Alzheimer's Disease (AD)

using a LC-MS/MS for primary metabolites in plasma. A method using a pentafluorophenylpropyl (PFPP) column enables the comprehensive analysis of 97 hydrophilic and hydrophobic primary metabolites. Using this approach the simultaneous analysis of amino acids, organic acids, nucleotides, nucleosides and co-enzymes was performed on 33 plasma samples from AD patients and 43 age- and sex-matched controls.

### Methods

Human plasma (20 µL) was prepared using a two-phase extraction with methyl tert-butyl ether (MTBE) and methanol/water. The methanol/water phase was injected directly into the LC-MS/MS. Data were processed using

LabSolutions and Traverse™ MS Multivariate Analysis Software for MRM Data (Shimadzu Corporation, Japan), SIMCA P 14.0 (Umetrics, Sweden) and R packages for further statistical analysis.

#### Liquid chromatography

LC system	: Shimadzu Nexera X2
Column	: Discovery HS F5-3 (150 x 2.1 mm, 3 µm)
Mobile phase A	: 0.1 % formic acid in water
Mobile phase B	: 0.1 % formic acid in acetonitrile
Flow rate	: 0.25 mL/min
Column temperature	: 40 °C
Injection volume	: 0.5 µL
Binary gradient	:

Time (mins)	%B	Time (mins)	%B
0.0	0	15.0	95
2.0	0	20.0	95
5.0	25	20.1	0
11.0	35	25.0	0

#### Mass spectrometry

MS system	: Shimadzu LCMS-8060
Ionisation	: Heated ESI (positive/negative)
Dwell time	: 5 msec
Pause time	: 1 msec
Polarity switching	: 5 msec
Source temperatures	: Interface: 350 °C Heat block: 300 °C Desolvation line: 150 °C
Gas flows	: Heated gas (air): 10 L/min Drying gas (N2): 10 L/min Nebulising gas (N2): 3 L/min



## Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS

### Results and discussion

Figure 1 shows a representative MRM chromatogram of the from a pooled quality control (QC) of all healthy controls and AD patient samples considered in this study. Peak area measurements for 62 metabolites were detected with CV < 30% across QC samples, used to

determine the level of metabolic change between control and AD patients. A number of these metabolites exhibited significant changes between control and AD samples by applying a t-test, with a summary of the most significant findings shown in Figure 2.




Figure 1 – Chromatogram of 62 metabolites detected in human plasma extract and overlaid metabolites exhibiting significant change between control and AD samples.

# Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS




Figure 2 – Pareto scaled plots for metabolites with most significant change between control and AD samples.

Of particular interest were the changes in the expression of neurotransmitters. As an example, the box plots in Figure 3 show the variation in metabolic changes in the serotonin synthesis pathway. From these results, we can

see the decrease of tryptophan and serotonin in the AD plasma (Figure 3A and B), which complement similar findings from measurements made in a separate study of brain tissue (Figure 3C and D).




Figure 3 – Box plots highlighting changes in tryptophan and serotonin levels between control and disease groups in plasma (A and B) and in brain tissue (C and D). Brain tissue analysis as part of a separate study; data not shown here.

## Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS

A reduction in tryptophan, coupled with an increase in the abundance of the aromatic amino acid decarboxylase (AAAD) inhibitor alpha-synuclein in the brain of AD patients, suggests a mechanism for the

reduction of serotonin in the brain. The reduction in the abundance of this monoamine neurotransmitter would result in impaired signal transmission in the brain of AD patients, leading to cognitive function decline (Figure 4).




Figure 4 – Illustration of serotonin synaptic transmission with normal (A) and reduced (B) serotonin levels

## Exploring Changes in Primary Metabolites in Alzheimer's Disease using Targeted LC-MS/MS

### Conclusions

- In this presentation we have shown the comprehensive analysis of primary metabolites in human plasma, which revealed metabolic changes between control and AD patients
- This targeted approach focused on primary metabolites provides a sensitive and selective way of exploring biochemical changes leading to AD
- Variation in a number of metabolites suggest perturbations in purine metabolism, the urea/TCA cycle and serotonin metabolism in AD
- Reduced plasma tryptophan and serotonin suggest a disturbance in neurotransmission, changes to which may result in reduced signal transduction in AD patients
- Acetylcholinesterase inhibitors are well established treatments for AD, and the results of this study suggest the need to consider the abundance of other neurotransmitters.

First Edition: October, 2016



Shimadzu Corporation  
[www.shimadzu.com/an/](http://www.shimadzu.com/an/)

**For Research Use Only. Not for use in diagnostic procedures.** Not available in the USA, Canada, and China.  
This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.